Postoperative Anti‐IgE Therapy for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Efficacy and Prognostic Factors

医学 奥马佐单抗 鼻息肉 布地奈德 哮喘 慢性鼻-鼻窦炎 鼻窦炎 内科学 功能性内窥镜鼻窦手术 前瞻性队列研究 外科 免疫球蛋白E 免疫学 抗体
作者
Xiaomei Yang,M Ye,Minghao Pan,Jiashu Zhao,Yang Liu,Xuelan Zeng,Wendong Liu,Yueqi Sun,Yi Wei,Fenghong Chen,Rui Xu
出处
期刊:International Forum of Allergy & Rhinology [Wiley]
卷期号:15 (11): 1245-1255 被引量:1
标识
DOI:10.1002/alr.23626
摘要

BACKGROUND: Omalizumab has demonstrated efficacy in treating chronic rhinosinusitis (CRS) with nasal polyps and comorbid asthma (NPwAS) in preoperative settings. However, real-world evidence regarding its postoperative application remains limited. This study aimed to assess the effectiveness and safety of omalizumab in managing NPwAS following endoscopic sinus surgery (ESS), and to identify predictors for treatment response. METHODS: This prospective observational study enrolled 60 NPwAS patients who underwent ESS between January 2020 and March 2023. Participants were divided into two groups: Control group (receiving standard care: nasal saline lavage and budesonide nasal spray) and Omalizumab group (receiving omalizumab in addition to standard care). Disease assessments, including total nasal symptom score (TNSS), visual analog scale (VAS) score, asthma control test (ACT), and sino-nasal outcome test-22 (SNOT-22), were conducted at baseline and 6 months post-treatment. Blood and nasal polyp tissue samples were collected to explore potential predictors. CRS disease control was categorized as controlled, partly controlled, or uncontrolled based on the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS). RESULTS: Thirty patients in the Omalizumab group and 28 in the Control group completed the treatment and follow-up. At 6 months, CRS control was significantly better in the Omalizumab group compared to the Control group, with response rates of 40% and 14.3%, respectively (p = 0.009). The Omalizumab group also demonstrated greater mean improvements from baseline in TNSS, loss of smell score, and SNOT-22 score compared to the Control group. The treatment exhibited a favorable safety profile. CONCLUSIONS: Omalizumab significantly improved clinical outcomes in NPwAS patients 6 months post-surgery, underscoring its potential as an effective adjunctive therapy in the postoperative management of NPwAS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hbutsj发布了新的文献求助10
1秒前
2秒前
丘比特的应助被FaFa采纳,获得10
2秒前
3秒前
4秒前
扶摇完成签到,获得积分10
4秒前
303完成签到 ,获得积分10
5秒前
6秒前
xx发布了新的文献求助10
7秒前
FaFa完成签到,获得积分10
7秒前
爆米花的应助被lilac采纳,获得10
7秒前
li完成签到 ,获得积分10
9秒前
11完成签到,获得积分10
9秒前
wangfei发布了新的文献求助10
9秒前
smy完成签到 ,获得积分10
9秒前
温暖的夏蓉完成签到 ,获得积分10
10秒前
10秒前
heee完成签到 ,获得积分10
11秒前
FashionBoy的应助被hml123采纳,获得10
11秒前
xxy完成签到,获得积分10
11秒前
qq完成签到,获得积分20
12秒前
12秒前
Lily发布了新的文献求助10
12秒前
123发布了新的文献求助10
12秒前
12秒前
芋头完成签到 ,获得积分20
13秒前
科研通AI6.3的应助被yyyhan采纳,获得10
13秒前
shell完成签到 ,获得积分10
13秒前
我是老大的应助被斯文的千秋采纳,获得10
13秒前
FUTURE完成签到,获得积分10
14秒前
DW发布了新的文献求助10
14秒前
DW发布了新的文献求助10
14秒前
15秒前
15秒前
我是老大的应助被喔喔佳佳L采纳,获得20
15秒前
第一作者发布了新的文献求助10
16秒前
似水流年发布了新的文献求助10
16秒前
16秒前
兮非发布了新的文献求助10
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157